human trial of an anti-tumour vaccine, page-5

Yep thats the emotional side the real value in the short term is in there Hiq cel treatment for humans and CryoShot and AdiCell for animals.
The company’s human products are currently used in 4 specialist clinics and its animal products in 70 veterinary clinics in Australia, and generated revenue of A$1.7M in FY13. We expect RGS to grow revenue to A$5M by FY15 by increasing the penetration ofthe Australian market, and by launching its human HiQCell product in overseas markets with a similar regulatory environment to Australia. The company also has an extensive pipeline of additional products.